OncoDiag
Focused on developing of non-invasive diagnostic tests for early detection of cancers.
| EUR | 2018 | 2019 | 2020 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
OncoDiag is a pioneering biotech company specializing in the development of innovative diagnostic tests for early cancer detection. The company serves healthcare providers, hospitals, and research institutions, primarily focusing on the European market. OncoDiag's business model revolves around the commercialization of proprietary diagnostic tests that utilize advanced biomarkers to identify various types of cancer, including colorectal and bladder cancer, at an early stage. These tests are designed to be non-invasive, providing a more comfortable and accessible alternative to traditional diagnostic methods like colonoscopies. Revenue is generated through the sale of diagnostic kits and related services, as well as through partnerships and licensing agreements with medical institutions and research organizations.
Keywords: cancer diagnostics, biomarkers, non-invasive tests, colorectal cancer, bladder cancer, healthcare providers, European market, diagnostic kits, medical partnerships, biotech innovation.